Ocugen Inc Stock, NASDAQ:OCGN
263 Great Valley Parkway, Suite 160, Malvern, Pennsylvania 19355
United States of America
Number of Employees: 15
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, and COVAXIN. The firm's Modifier Gene Therapy Platform engages to address retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.